We identify ADAR1, an RNA editing enzyme with transient nucleolar localization, as a novel substrate for sumoylation. We show that ADAR1 co-localizes with SUMO-1 in a sub-nucleolar region that is distinct from the fibrillar center, the dense fibrillar component and the granular component. Our results further show that human ADAR1 is modified by SUMO-1 on lysine residue 418. An arginine substitution of K418 abolishes SUMO-1 conjugation and although it does not interfere with ADAR1 proper localization it stimulates the ability of the enzyme to edit RNA both in vivo and in vitro.
INTRODUCTION
A defining feature of eukaryotic cells is the generation of protein diversity either posttranscriptionally by alternative splicing and RNA editing or post-translationally by modification of amino acids in proteins. One of the most recently discovered posttranslational modification mechanism in eukaryotes involves the covalent attachment of the small ubiquitin-like modifier, SUMO, to target proteins. Modification of proteins by SUMO, or sumoylation, plays crucial regulatory roles in eukaryotes. Proteins known to be modified by SUMO include, between others, RanGAP1, PCNA, IκBα, p53, c-jun, topoisomerases, promyelocytic leukaemia protein (PML), Sp100 and the mitogen activated protein kinase kinase 1 (MEKK1). Many SUMO substrates are transcription factors and co-factors, or proteins implicated in DNA repair and replication (reviewed by (Hay, 2001; Melchior et al., 2003; Seeler and Dejean, 2003; Hay, 2005) ). Although it is well established that SUMO can affect target protein function by altering its subcellular localization, activity, or stability, for many substrates the biological functions of sumoylation remain unknown.
Sumoylation is a reversible and highly dynamic process that involves formation of an isopeptide bond between the C-terminus of SUMO and the ε-amino group of a lysine residue of the target protein. The most intensely studied human form of SUMO is the SUMO-1 protein, which is 48% identical to yeast Smt3 (Bayer et al., 1998; Mossessova and Lima, 2000) . In vertebrates there are at least three additional proteins. SUMO-2 and SUMO-3 are ~45% identical to SUMO-1 (Saitoh and Hinchey, 2000) , and shows an 86% amino acid homology to SUMO-2 (Bohren et al., 2004) . SUMO is conjugated to protein substrates via an ATP-dependent enzymatic pathway that is mechanistically similar to ubiquitination. The reaction requires a SUMO protease that removes four amino acids from the C-terminus of the 101-amino acid SUMO-1 precursor to generate the mature form; an heterodimeric SUMO-activating enzyme, SAE1/2; Ubc9, a SUMO-conjugating enzyme that ligates directly to its protein target;
and an E3-like SUMO ligase (reviewed (Melchior et al., 2003) ). Three SUMO E3s have been identified so far: the mammalian protein inhibitors of activated STAT (PIAS) (Sachdev et al., 2001) , the nucleoporin RanBP2 (Azuma and Dasso, 2002; Pichler et al., 2002) and the polycomb group protein PC2 (Kagey et al., 2003) . Recent structural data provide novel insights into the mechanism used by E3s to enhance SUMO conjugation (Duda and Schulman, 2005; Reverter and Lima, 2005; Tatham et al., 2005) .
Removal of SUMO from proteins is carried out by specific cysteine proteases that have both hydrolase and isopeptidase activity Hochstrasser, 1999, 2000) . Most enzymes involved in the SUMO pathway are localized in the nucleus, and it is therefore believed that sumoylation is predominantly a nuclear process (Rodriguez et al., 2001; Zhang et al., 2002; Seeler and Dejean, 2003) .
Here, we describe that proteins modified by SUMO-1 are present in the nucleolus, that SUMO-1 in the nucleolus co-localizes with the RNA editing enzyme ADAR1 and that this enzyme represents a novel substrate for sumoylation. ADAR1 (adenosine deaminase that acts on RNA) is a member of the family of enzymes that catalyse the conversion of adenosine to inosine in double-stranded RNA (dsRNA) (reviewed in (Keegan et al., 2001; Bass, 2002; Schaub and Keller, 2002) . Since inosine acts as guanosine during translation, A-to-I conversion in coding sequences leads to amino acid changes and often entails changes in protein function. In addition to amino acid changes, A-to-I RNA editing can also occur in 5' and 3' UTR (Morse and Bass, 1999) , in introns (Higuchi et al., 1993) and at splicing branch site (Beghini et al., 2000) .
Editing can also generate a 3' splice acceptor (Rueter et al., 1999) and relieve a stop codon (Polson et al., 1996) . In mammals there are three ADAR enzymes, termed ADAR1, ADAR2, and ADAR3. Inactivation of editing enzymes in mice (Higuchi et al., 2000) and in the fruit fly (Palladino et al., 2000b) has resulted in profound neurological phenotypes. All ADAR proteins have a highly conserved catalytic domain at the Cterminus and one to three double-stranded RNA-binding domains. ADAR1 differs from the other members of the family in its extended N-terminus that is enriched in RG residues and contains two tandemly arranged Z-DNA-binding domains (Keegan et al., 2001; Keegan et al., 2004) . In humans, there are two ADAR1 forms: a 150 KDa protein (comprising amino acids 1-1226) that is induced by interferon and localizes predominantly in the cytoplasm, and a 110 KDa protein (encompassing residues 296-1226) that is constitutively expressed and localizes to the nucleus (Patterson and Samuel, 1995; George and Samuel, 1999b, a) .
Several lines of evidence suggest that ADAR activity is tightly controlled in the cell.
ADARs act as dimers and heterodimer formation between different ADAR forms can contribute to regulate enzyme activity and substrate specificity (Cho et al., 2003; Gallo et al., 2003) . In Drosophila, ADAR can edit its own pre-mRNA (Palladino et al., 2000a) , whereas in mammals a self-editing process leads to alternative splicing of ADAR2 (Rueter et al., 1999) . Furthermore, ADAR1 expression in mammals is regulated by interferon (Patterson and Samuel, 1995) .
In this work we demonstrate that ADAR1 is modified by SUMO at lysine residue 418.
Substitution of this amino acid residue by arginine, which cannot be modified by SUMO, affects the editing activity of the enzyme. Our results therefore suggest a novel role for SUMO in regulating ADAR1 editing activity.
MATERIALS AND METHODS

Antibodies
Endogenous ADAR1 was detected with rabbit polyclonal antibodies (Ab 007 and Ab 668) (Desterro et al., 2003) . Proteins tagged with a histidine hexamer were detected with an anti-His monoclonal antibody (Qiagen), and hemaglutinin-tagged proteins were detected with the anti-HA monoclonal antibody mAb 11 (Babco). Green fluorescence protein (GFP) was detected with a mixture of two mouse monoclonal antibodies (anti-GFP clones 7.1 and 13.1) (Boehringer Mannheim) and endogenous SUMO-1 was detected with a rabbit polyclonal antibody (Santa Cruz Biotechnology). PML was detected with anti-PML mouse monoclonal antibody (PGM-3; Santa Cruz Biotechnology). Additionally, the following antibodies were used to detect nucleolar proteins: anti-B23/nucleophosmin goat polyclonal antibody C-19 (Santa Cruz Biotechnology); anti-fibrillarin monoclonal antibody 71B9 (Reimer et al., 1987) ; anti-UBF rabbit polyclonal antibody E29 (O'Mahony et al., 1992) ; and auto-immune human anti-RNA polymerase I serum S18 (kindly provided by Dr U. Scheer).
Plasmids
Plasmids expressing full-length hADAR1 (Desterro et al., 2003) , the RC construct (Herbert et al., 2002) and GFP-SUMO (Gostissa et al., 1999) have been described previously.
Site directed mutagenesis
The point mutation in the lysine within the SUMO-1 consensus sequence was generated by oligonucleotide-directed mutagenesis using the QuickChange site directed mutagenesis kit (Stratagene) and the following oligonucleotides: 5'-6 GGAACCTGTCATAAGGTTAGAAAACAGGC-3' and 5'-GCCTGTTTTCTAACCTTATGACAGGTTCC-3'. The nucleotides changed in this mutagenesis are indicated in bold.
Mutagenesis was performed on ADAR1 cloned in different plasmids, pEGFP, pFlis and pPICZA but always with the same set of oligonucleotides. All constructs were confirmed by DNA sequencing. (Rodriguez et al., 1999) .
Cell culture and transfections
Immunofluorescence
Cells on coverslips were briefly rinsed with PBS, fixed in 3.7% formaldehyde (freshly prepared from paraformaldehyde), diluted in PBS for 10 minutes at room temperature and washed with PBS. The cells were then permeabilized with 0.5% triton X-100 for 15 minutes or 0.05% SDS for 10 minutes at room temperature and washed with PBS.
Immunofluorescence and confocal microscopy was performed as described (Calado et al., 2000) .
In situ hybridization
GluR-B DNA was obtained by SmaI and XbaI digestion of the GluR-B/pRK plasmid (Higuchi et al., 1993) and RC DNA from EcoRI and XbaI digestion of the RC plasmid (Herbert et al., 2002) . Both fragments were purified, labelled with digoxigenin-11-dUTP by nick translation and used as probes for in situ hybridization. Cells were fixed and permeabilized as described previously for immunofluorescence. Immediately before hybridization, cells were incubated in hybridization mixture for 5 minutes at 37 C. Cells were hybridized for 4 hours at 37 C in 50% formamide, 2X SSC, 10% dextran sulphate, 50 nM sodium phosphate pH 7.0 with probes at 2 ng/μl. Post-hybridization washes were in 50% formamide, 2X SSC (three times for 5 minutes at 45 C) and in 2X SSC (three times for 5 minutes at 45 C). The sites of hybridization were visualized with cy3 antidigoxigenin secondary antibody (Molecular Probes) diluted in 4X SSC-Tween, 2%
bovine serum albumin, 0,2% gelatine.
Microscopy
Samples were examined on a Zeiss LSM 510 microscope with a Planapochromat 63X/1.4 objective.
Western blot analysis
Western-blot analysis of transfected cells was performed with whole cell extracts that were prepared in SDS sample buffer. Lysates were boiled for 10 minutes prior to electrophoresis on either 8.5% or 10% polyacrylamide gels and transferred to a nitrocellulose membrane by electroblotting. Anti-His, anti-ADAR1 and anti-GFP were used as primary antibodies. Horseradish peroxidase-conjugated anti-mouse IgG and antirabbit IgG (Bio-Rad Laboratories) were used as secondary antibodies. Blots were developed with the enhanced chemiluminescence detection system (Amersham Biosciences).
Expression and Purification of Recombinant Proteins
SUMO-1, Ubc9 and SAE1/SAE2 were expressed and purified from E. coli B834 as described previously (Desterro et al., 1997; Tatham et al., 2001) . Both ADAR wild type and K418R mutant were over-expressed in the yeast Pichia pastoris and purified as described (Gallo et al., 2003) .
In vitro expression of proteins
In vitro coupled transcription/ translation of ADAR1 proteins was performed with 1μg
of plasmid DNA and a wheat germ-coupled transcription/ translation system according to the manufacturer's instructions (Promega). 35 S-methionine (Amersham Biosciences) was used in the reactions to generate radiolabeled protein.
In vitro SUMO-1 conjugation assay
SUMO-1 conjugation assays were performed in 10μl reactions containing an ATP regenerating system, 1μl of 35 S-methionine labelled ADAR1 or 10 ng of either WT or K418R purified recombinant ADAR1 and purified recombinant SUMO-1, Ubc9 and 9 SAE proteins as previously described (Tatham et al., 2001) . Reaction products were analysed by SDS-PAGE and either detected by western blotting analysis using an anti-ADAR1 antibody or the gel was dried prior to overnight exposure to film.
In vitro editing
The non-specific dsRNA substrate, a shorter form of BScat was prepared by in vitro transcription as previously reported and the editing assay was performed as previously described (O'Connell and Keller, 1994) . The assay mixture contained dsRNA containing 200 fmoles of 32 P-labeled adenosine and the reaction was performed at 37°C
for 60 minutes with purified recombinant ADAR1-WT and ADAR1-K418R.
Analysis of editing of a transcript encoded by the GluR-B mini gene B13 was performed by primer extension assay with the BHS-RT primer specific for hotspot1 as previously described (Melcher et al., 1995) . In the assay 10 fmol of in vitro transcribed RNA was incubated with either purified recombinant protein or previously in vitro SUMO-1 modified protein for 1 hour at 37ºC. The reaction mixture was then treated with proteinase K for 30 min., phenol/chloroformed extracted and ethanol precipitated.
10 fmols of radioactive BHS-RT primer was added and annealed at 52ºC overnight.
Subsequently an RT reaction was performed in the presence of ddTTP and after ethanol precipitation the extension products were electrophoresised on a 15% denaturing polyacrylamide gel. The gel was dried and quantified on a PhosphorImager.
RESULTS
Proteins modified by SUMO-1 localise to the nucleolus
To date, most known sumoylated proteins are either nuclear proteins or proteins that shuttle to the nucleus. Within the nucleus, proteins modified by SUMO have been localized to the nucleoplasm, PML nuclear bodies and nuclear pore complexes (Melchior et al., 2003; Seeler and Dejean, 2003) . To further characterize the subcellular distribution of SUMO-conjugated proteins, a fusion of SUMO-1 to the green fluorescence protein (GFP-SUMO-1) was transiently expressed in HeLa cells. GFP-SUMO-1 can replace endogenous SUMO (pmt3) in fission yeast suggesting that the GFP tag does not interfere with SUMO-1 function in vivo (Tanaka et al., 1999) .
Analysis of HeLa cells expressing GFP-SUMO-1 reveals nuclear staining with accumulation at the nuclear pore complexes and in nuclear bodies, as previously described ( Figure 1A , arrows and arrowheads). Surprisingly, an additional nucleolar staining is observed ( Figure 1A , dashed lines). To confirm that the detection of GFP-SUMO-1 in the nucleolus corresponds to the presence of modified proteins, HeLa cells were transfected with GFP-SUMO-1Δ6. This mutant form of SUMO-1 lacks the Cterminal Gly-Gly motif, and therefore cannot be conjugated to substrates (Johnson et al., 1997) . Western blot analysis using antibodies against GFP shows that GFP-SUMO-1Δ6 is detected as a single band of the expected size ( Figure 1B , arrow), whereas fulllength GFP-SUMO-1 is detected as a high-molecular-weight smear of conjugated products, indicating that this GFP fusion protein is effectively conjugated. As shown in Figure 1A , GFP-SUMO-1Δ6 distributes throughout the cytoplasm and nucleoplasm, with no concentration at the nuclear periphery, nuclear bodies or the nucleolus. Thus, localization of SUMO-1 to the nucleolus depends on its ability to bind to substrates.
This strongly suggests that proteins modified by SUMO-1 are present in the nucleolus.
Immunolabeling experiments of GFP-SUMO-1 expressing cells with an anti-PML antibody demonstrate that the nucleolar staining does not correspond to PML bodies ( Figure 1C) . Staining of the nucleolus is also detected by immunofluorescence microscopy using a rabbit polyclonal antibody raised against SUMO-1 ( Figure 1D ).
Next, we analysed in more detail the sub-nucleolar distribution of SUMO-1. In mammalian cells, the nucleolus comprises three major regions involved in ribosomal biogenesis: the fibrillar centers, the dense fibrillar component and the granular component . Transcription of rRNA genes localized at the fibrillar centers produces rRNA precursors (pre-rRNAs) that move away from the rDNA template and undergo a series of post-transcriptional processing reactions. The initial processing steps occur while the pre-rRNAs reside in the dense fibrillar component, whereas late processing events take place in the granular component.
Reflecting the vectorial organisation of ribosomal synthesis, the fibrillar centers contain proteins required for transcription of the rRNA genes, notably RNA polymerase I (pol I) and the pol I transcription initiation factor UBF (upstream binding factor); the dense fibrillar component contains proteins involved in early steps of pre-rRNA processing such as fibrillarin; and the granular component is highly enriched in proteins involved in the assembly of pre-ribossomes, an example of which is B23 also called nucleophosmin (Scheer et al., 1993) . Double-labelling of HeLa cells expressing GFP-SUMO-1 with antibodies specific for RNA polymerase I, UBF, fibrillarin and nucleophosmin reveals lack of co-localization ( Figure 1E ). Thus, the major fraction of nucleolar proteins modified by SUMO-1 does not associate with the well described sub-nucleolar regions implicated in ribosome biogenesis.
ADAR1 is modified by SUMO-1 in vitro and in vivo
We have recently shown that the RNA editing enzymes ADAR1 and ADAR2 localise transiently to the nucleolus in a region that is distinct from the fibrillar centers, the dense fibrillar component and the granular component (Desterro et al., 2003) . We therefore double-labelled HeLa cells expressing GFP-SUMO-1 with an antibody specific for ADAR1 (Figure 2A ). This antibody, which recognizes both forms of human ADAR1, labels the cytoplasm and the nucleoplasm, with additional staining of the nucleolus (Desterro et al., 2003) . The results show a perfect co-localisation at the nucleolus, raising the possibility that ADAR1 is a target for SUMO-1 conjugation. Most of the proteins modified by SUMO-1 contain the consensus motif ΨKXE, where Ψ is a hydrophobic large amino acid, K the modified lysine, X any amino acid and E a glutamatic acid (Rodriguez et al., 2001) . Sequence analysis of the long form of ADAR1
(amino acids 1-1226) shows two lysines that conform to this consensus sequence ( Figure 2B ). To determine whether any of these lysine residues is a substrate for SUMO-1 modification,
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S-labeled ADAR1 was generated in vitro by a coupled transcription/translation reaction and incubated in an ATP regenerating system with purified recombinant components required for SUMO modification, SUMO, SUMO-1
Activating enzyme (SAE) and UBC9. As a previously described substrate,
S-labeled Sp100, was used as positive control in the reaction (Sternsdorf et al., 1997) . Analysis of the reaction products by SDS-PAGE indicates that a proportion of ADAR1 is converted to a more slowly migrating form that is dependent on the presence of SUMO reaction components ( Figure 3A, lanes 2, 3 and 4) . Substitution of SUMO-1 for GST-SUMO-1 alters the mobility of the more slowly migrating form which confirms that the mobility shift is due to SUMO modification ( Figure 3A, lane 3) . Furthermore, ADAR1 is also modified by SUMO-2, a SUMO-1 related protein ( Figure 3A , lane 4). Analysis of deletion variants of ADAR1 reveals that a truncated version of the protein encompassing amino acid residues 1-442 is modified by SUMO-1 in vitro ( Figure 3B , lanes 1, 2). In contrast, no modification is detected in a truncated variant that consists of amino acid residues 442-1226 (Fig. 3B, lanes 3, 4) . Thus, it is likely that ADAR-1 is modified by SUMO-1 on lysine 418. To confirm this hypothesis, lysine 418 was mutated to an arginine (K418R) and the protein assayed for SUMO-1 modification.
ADAR1 containing this single point mutation is no longer modified in vitro by SUMO-1 ( Figure Figure 3B ). We therefore consider that the putative modification at the additional residue depends on the N-terminus consensus site. Taken together, our in vitro and in vivo data demonstrate that ADAR1 is modified by SUMO-1
and that the major acceptor site for this modification is lysine residue 418.
The sub-cellular distribution of ADAR1 is independent from modification by
SUMO-1
Since SUMO-1 modification can alter the localization of target proteins, we decided to investigate whether this modification modulates ADAR1 sub-cellular distribution.
When HeLa cells are transfected with full-length hADAR1 tagged with GFP at the Nterminus, the fusion protein (GFP-ADAR1) is detected predominantly in the cytoplasm (Desterro et al., 2003) . Although at steady-state this fusion protein appears exclusively cytoplasmic, GFP-ADAR1 shuttles constantly between the nucleus and the cytoplasm due to a CRM1-dependent nuclear export signal (NES) (Poulsen et al., 2001; Desterro et al., 2003) . Treatment of cells with Leptomycin B (LMB), a specific CRM1 inhibitor, prevents nuclear export, causing accumulation of the protein in the nucleus with higher concentration in the nucleolus (Poulsen et al., 2001; Desterro et al., 2003) . As shown in Figure 5 , similar results are observed in cells that express either ADAR1-WT or ADAR1-K418R, the mutant variant that fails to be modified by SUMO-1. Thus, SUMO-1 modification appears dispensable for nucleo-cytoplasmic shuttling and nucleolar targeting of ADAR1, but one cannot exclude that the mutant can form a dimer with endogenous WT protein and be correctly targeted (Gallo et al., 2003) .
Recent studies have shown that ADAR1 is in constant flux in and out of the nucleolus and that when cells express the editing-competent glutamate receptor GluR-B mini gene B13 in the nucleoplasm, ADAR1 is no longer detected in the nucleolus (Desterro et al., 2003; Sansam et al., 2003) . To investigate whether the nucleolar SUMO-1 signal is dependent on the presence of ADAR1 in the nucleolus, HeLa cells were co-transfected with GFP-SUMO-1 and a plasmid containing the editing-competent murine GluR-B mini gene B13 (Higuchi et al., 1993) . Visualisation of GluR-B mini gene B13 by fluorescence in situ hybridisation reveals staining of the nucleoplasm excluding the nucleolus ( Figure 6A ). In cells that express GluR-B mini gene B13, endogenous ADAR1 becomes excluded from nucleolus ( Figure 6B ). However, in these cells the localization pattern of GFP-SUMO-1 in the nucleolus remains unaltered ( Figure 6C ).
This suggests that distinct, not yet identified nuclear proteins modified by SUMO-1 colocalize with ADAR1 in the same sub-nucleolar compartment.
Modification of ADAR1 by SUMO-1 reduces RNA editing activity
The ability of SUMO to directly affect the activity of an enzyme has only been described for the thymine DNA glycosylase (TDG). SUMO-1 conjugation of TDG reduces its DNA substrate binding affinity and induces higher enzymatic turnover (Hardeland et al., 2002) . To investigate whether the modification of ADAR1 by SUMO-1 affects RNA editing activity, we performed in vivo and in vitro experiments.
First, we took advantage of the editing reporter construct described by Herbert et al (Herbert et al., 2002) . The RC reporter was designed with two start codons and a stop codon. The first start codon is not used under normal circunstances, and the stop codon is embedded in a short stretch of dsRNA that is recognised as an editing substrate by ADAR1. A to I editing converts the stop codon (UAG) into UIG, allowing translation from the first start codon. This results in production of a fusion protein that contains both HA and GFP tags. If the reporter mRNA is not edited, the stop codon is not eliminated and translation of the messenger starts in the second start codon giving rise to a GFP fusion protein that lacks the N-terminal HA tag ( Figure 7A) . Therefore, the expression of an HA-tagged fusion protein is editing-dependent. The RC construct was to enhance sumoylation of ADAR1 in vivo. In fact, there is evidence that modification of proteins by SUMO is a tightly regulated process in the cell (Melchior et al., 2003; Marx, 2005) .
The labile nature of SUMO-1 modification due to the high activity of SUMO specific proteases and the absence of a mechanism to induce SUMO-1 modification in vivo, do not facilitate the investigation of a direct effect of SUMO-1 on ADAR1 activity in the cell. We therefore decided to perform further studies using in vitro systems. Both ADAR1-WT and ADAR1-K418R were expressed in the yeast Pichia pastoris, and the recombinant proteins containing HIS and FLAG tags were purified to homogeneity by chromatography over both Ni
2+
-NTA and FLAG affinity matrices (Ring et al., 2004) .
Consistent with the in vivo data, the in vitro results indicate that recombinant ADAR1-WT is consistently less active than recombinant ADAR1-K418R in editing a long duplex RNA in a non-specific assay ( Figure 8A ) (O'Connell and Keller, 1994) .
Western-blot analysis of the recombinant proteins confirmed that a fraction of ADAR1-WT is modified by SUMO-1 (data not shown). This observation prompted us to compare the editing activity of ADAR1-WT and ADAR1-K418R recombinant proteins on a specific substrate, the GluR-B mini gene B13 ( Figure 8B) . A primer extension assay was performed in triplicate on a transcript encoded by the GluR-B mini gene B13 (Higuchi et al., 1993) . As clearly shown in Figure 8B , following in vitro modification of the recombinant proteins by SUMO-1, the editing activity of wild type ADAR1, and not of the K418R mutant, is significantly reduced. A range of different amounts of recombinant proteins was tested in this assay and reproducible results were obtained ( Figure 8B ). Western blot analysis confirms the modification of ADAR1-WT ( Figure   8C , lane 2), but not of the mutant ADAR1-K418R ( Figure 8C , lane 3). Consistent with the view that sumoylation is not required for editing, addition of ATP is dispensable for recombinant ADAR1 activity in vitro (O'Connell and Keller, 1994) , whereas if SUMO-1 modification was necessary ATP addition would be essential. Taken together these results support a direct role of SUMO-1 modification on reducing the RNA editing activity of ADAR1.
DISCUSSION
Post-translational modification of proteins by SUMO is known to play a regulatory role in many cellular processes, and the identification of novel SUMO-targeted proteins is currently attracting much attention (for recent reviews see (Johnson, 2004) (Melchior et al., 2003) ). In general, only a limited fraction of a certain protein is modified by SUMO in the cell, making it difficult to detect the low abundant pool of endogenously sumoylated proteins. In this study we show that GFP-tagged SUMO-1 accumulates in the nucleolus. In contrast, a GFP-tagged mutant version of SUMO-1 that lacks the Cterminal amino acids required for covalent attachment to target proteins fails to localise to the nucleolus ( Figure 1A and 1B). Similar results were very recently reported by
Ayaydin and Dasso who observed that YFP-SUMO-1, but not YFP-SUMO-2 or YFP-SUMO-3, localizes to the nucleolus (Ayaydin and Dasso, 2004) . This strongly suggests that a subset of nucleolar proteins is modified by SUMO. Interestingly, some of the enzymes involved in the sumoylation pathway have been previously localised to the nucleolus, namely the E3 SUMO-1 ligase PIAS1 (Valdez et al., 1997) , and the SUMO/Smt3-1 specific isopeptidase SMT3IP1 (SENP3) (Nishida et al., 2000; Leung et al., 2003) . Thus, it is possible that certain protein targets are reversibly modified by SUMO-1 in the nucleolus.
Noteworthy, SUMO was not detected in recent MS studies on isolated nucleoli from
HeLa cells (Scheer et al., 1993; Andersen et al., 2002) . However, this is not surprising taking into account that many endogenously sumoylated proteins are present at a level below normal detection limit. Moreover, sumoylation is a highly dynamic and reversible reaction, making it difficult to preserve SUMO-conjugation during cell fractionation and sub-cellular purification procedures.
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The nucleolus is a sub-nuclear compartment dedicated to the biogenesis of ribosomes.
The nucleolus is where the rRNA genes are kept and transcribed and the rRNAs are processed and assembled with proteins to form pre-ribosomes. However, an increasing body of evidence indicates that the nucleolus is not exclusively a ribosome factory, but plays additional roles in the cell. According to a current view, the nucleolus may act as a molecular "safe" or "sink" that regulates protein activity by sequestration (review (Leung et al., 2003) ).
DNA topoisomerase I (topo I) is a nuclear protein that concentrates in the nucleolus and is modified by SUMO. However, topo I rapidly moves out of the nucleolus, and this nucleolar delocalisation is associated with conjugation of the protein with SUMO (Mo et al., 2002) . Thus, to date, no nucleolar proteins modified by SUMO were identified. In the present work we show that GFP-tagged SUMO-1 accumulates in a nucleolar region that is distinct from the well characterised nucleolar domains involved in ribosomal biogenesis, i.e., the fibrillar center, the dense fibrillar component and the granular component ( Figure 1E ). Rather, GFP-SUMO-1 co-localises precisely with the RNAediting enzyme ADAR1 (Figure 2 ). We further provide in vitro and in vivo evidence that human ADAR1 is modified by SUMO-1 on lysine residue 418 (Figure 3, 4) .
Importantly, the nucleolar localization of GFP-SUMO-1 remains unaltered when ADAR1 is no longer detected in that compartment (Figure 6 ), arguing that SUMO-1 modifies additional protein substrates in the nucleolus.
Although ADAR1 co-localises with ADAR2 in the nucleolus (Desterro et al., 2003) , the ADAR2 protein lacks the amino-terminal region containing the SUMO conjugation site.
Sequence analysis of ADAR2 does not reveal any SUMO-1 consensus motif and ADAR2 is not modified by SUMO-1 in vitro (data not shown). Because both ADAR1
and ADAR2 concentrate in the nucleolus and only ADAR1 is modified by SUMO, it is 20 unlikely that sumoylation of ADAR1 is required for targeting the enzyme to the nucleolus. According to this prediction, a mutant form of ADAR1 that is not sumoylated because it contains an arginine substitution of lysine 418 (ADAR1-K418R) localises to the nucleolus similarly to the wild type protein ( Figure 5 ).
Our work further provides in vivo and in vitro evidence that modification of ADAR1 by SUMO reduces the RNA editing activity of the enzyme. ADAR1 can edit RNAs both in a specific and non-specific manner, depending on the nature of the substrate. ADAR1
can edit specific transcripts encoding receptor proteins of CNS and these can result in recoding events. The best studied specific mammalian substrates for ADAR1 are the pre-mRNAs encoding the serotonin HT-2c receptor and those encoding ionotropic glutamate receptor (GluR) subunits. However, more recent studies have identified widespread A-to-I RNA editing sites in the human transcriptome (Athanasiadis et al., 2004; Kim et al., 2004; Levanon et al., 2004) . Approximately 1,500 human mRNAs were found to be subject to RNA editing at more than 13,000 sites that typically map in Alu repeats. Additionally, micro RNA precursors have been shown to be modified by A-to-I editing (Luciano et al., 2004) , and ADAR1 was implicated in gene silencing by short interfering RNA (Yang et al., 2005) .
Here we show that the mutant form of ADAR1 that is not modified by SUMO (ADAR1-K418R) is more active than the wild type enzyme in editing a reporter RNA in vivo, and modification of the wild type enzyme by SUMO reduces editing of a GluR-B mini gene B13 in vitro (Figures 7 and 8 ). This represents the first indication that sumoylation can contribute to regulate RNA editing activity.
ADAR activity is known to be tightly regulated in different species. In vertebrates,
ADARs shuttle between the cytoplasm, nucleoplasm and the nucleolus (Desterro et al., 2003; Sansam et al., 2003) , and it is currently thought that sequestration in the nucleolus contributes to prevent aberrant editing activity in the nucleoplasm. Based on our observations that ADAR1 co-localizes with SUMO-1 in the nucleolus and that sumoylation of ADAR1 reduces editing activity, we propose that the nucleolus represents a "sink" for inactive ADAR1 in the cell. In agreement with this view, it has been recently reported that ADAR2-but not ADAR1-mediated RNA editing occurs in the nucleolus (Vitali et al., 2005) . Considering that both ADAR1 and ADAR2 colocalize in the nucleolus, it was unexpected to find that ADAR1 does not perform nucleolar RNA editing. This apparent inconsistency can be explained by our findings suggesting that SUMO-1 conjugation renders ADAR1 inactive in the nucleolus while ADAR2 is not modified by SUMO.
Whether ADAR1 is preferentially sumoylated in the nucleolus remains to be established. Another important issue to be addressed concerns the mechanism by which sumoylation affects editing activity. Interestingly, ADAR enzymes act as a dimer and dimerization is essential for editing activity. It remains to be elucidated how the monomers bind to dsRNA and dimerize. Preliminary results for ADAR1 have shown that the N-terminal region containing the Z-DNA domain is not required as heterodimers can form between the p150 and p110 isoforms of ADAR1 (Cho et al., 2003) . However, the minimum region required for the dimerization of Drosophila ADAR is the N-terminus including and the first dsRNA-binding domain (dsRBD) (Gallo et al., 2003) . Dimerization affects the enzymatic activity as well as substrate specificity of ADAR1 and ADAR2 and is essential for editing activity in Drosophila (Gallo et al., 2003) .Considering that the SUMO-1 acceptor lysine lies between the Z-DNA and the first dsRBD one could consider SUMO as a stereochemical obstacle for both binding to the dsRNA and subsequent dimerization.
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In conclusion, together with the recent finding that SUMO modifies several heterogeneous nuclear ribonucleoproteins, which are key players in mRNA biogenesis (Li et al., 2004) , our results support a novel role for sumoylation in regulating RNA metabolism. A. HeLa cell expressing GFP-SUMO-1 (green staining) and immuno-labeled with an antibody directed against ADAR1 (Ab 007, red staining). This antibody recognizes both the long (150 KDa) and the short (110 KDa) forms of endogenous ADAR1. The long form of the protein is predominantly cytoplasmic, whereas the short form is nuclear. In some cell nuclei, ADAR1 is detected in discrete regions within the nucleolus, as 31 previously described (Desterro et al., 2003) . 
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